Argos Therapeutics (ARGS) 10-Q 9 Aug 17 2017 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2017	Aug. 02, 2017
Document Information [Line Items]
Entity Registrant Name	ARGOS THERAPEUTICS INC
Entity Central Index Key	1,105,533
Trading Symbol	args
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		54,974,739
Document Type	10-Q
Document Period End Date	Jun. 30, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q2
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Current assets
Cash and Cash Equivalents, at Carrying Value	$ 9,337,084	$ 52,973,376
Restricted cash	740,000
Assets held for sale	10,341,529	1,452,172
Prepaid expenses	1,431,473	940,106
Other receivables	42,193	136,140
Total current assets	21,892,279	55,501,794
Property and equipment, net	4,054,990	40,951,577
Restricted cash		740,000
Other assets	11,020	11,020
Total assets	25,958,289	97,204,391
Current liabilities
Accounts payable	794,278	5,377,377
Accrued expenses	7,385,997	9,980,891
Current portion of restructuring obligation	292,951
Current portion of notes payable	17,871	11,475,480
Current portion of manufacturing research and development obligation	5,273,458	3,653,203
Total current liabilities	14,483,622	30,609,838
Convertible note payable to related party	6,015,616
Long-term portion of notes payable	6,579,596	18,673,298
Long-term portion of manufacturing research and development obligation	3,070,463	4,509,033
Deferred liabilities	6,668,500	6,723,500
Warrants	746,300	20,926,061
Commitments
Stockholders’ equity (deficit)
Preferred stock $0.001 par value; 5,000,000 shares authorized as of December 31, 2016 and June 30, 2017; 0 shares issued and outstanding as of December 31, 2016 and June 30, 2017	0	0
Common stock $0.001 par value; 200,000,000 shares authorized as of December 31, 2016 and June 30, 2017; 41,263,179 and 42,229,330 shares issued and outstanding as of December 31, 2016 and June 30, 2017, respectively	42,229	41,263
Accumulated other comprehensive loss	(130,255)	(134,208)
Additional paid-in capital	344,120,299	338,249,457
Accumulated deficit	(364,605,507)	(331,986,817)
Total stockholders’ equity (deficit)	(20,573,234)	6,169,695
Total liabilities and stockholders’ equity (deficit)	25,958,289	97,204,391
Lease Agreement [Member]
Current liabilities
Current portion of lease obligations	588,620
Long-term portion of lease obligations	6,801,380	7,390,000
Power Generation Agreements [Member]
Current liabilities
Current portion of lease obligations	130,447	122,887
Long-term portion of lease obligations	$ 2,166,046	$ 2,202,966

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Jun. 30, 2017	Dec. 31, 2016
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	200,000,000	200,000,000
Common stock, shares issued (in shares)	42,229,330	41,263,179
Common stock, shares outstanding (in shares)	42,229,330	41,263,179

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Revenue	$ 69,693	$ 488,643	$ 174,952	$ 635,072
Operating expenses
Research and development	5,120,952	9,164,184	13,034,781	18,666,160
General and administrative	2,679,867	3,389,479	6,642,758	6,364,503
Impairment loss on property and equipment			27,204,349
Restructuring costs	344,474		5,352,766
Total operating expenses	8,145,293	12,553,663	52,234,654	25,030,663
Operating loss	(8,075,600)	(12,065,020)	(52,059,702)	(24,395,591)
Other income (expense)
Interest income	8,881	2,237	39,458	3,813
Interest expense	(294,329)	(543,462)	(1,022,760)	(1,034,655)
Gain on early extinguishment of debt			249,458
Change in fair value of warrant liability	(177,563)		20,179,761
Other expense			(4,905)
Other income (expense), net	(463,011)	(541,225)	19,441,012	(1,030,842)
Net loss	$ (8,538,611)	$ (12,606,245)	$ (32,618,690)	$ (25,426,433)
Net loss per share, basic and diluted (in dollars per share)	$ (0.21)	$ (0.48)	$ (0.79)	$ (1.04)
Weighted average common shares outstanding, basic and diluted (in shares)	41,374,852	26,066,160	41,344,356	24,336,393

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Net loss	$ (8,538,611)	$ (12,606,245)	$ (32,618,690)	$ (25,426,433)
Other comprehensive gain
Foreign currency translation gain	2,628	181	3,953	8,137
Unrealized gain on short-term investments				271
Total comprehensive loss	$ (8,535,983)	$ (12,606,064)	$ (32,614,737)	$ (25,418,025)

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Cash flows from operating activities
Net loss	$ (32,618,690)	$ (25,426,433)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization	490,701	439,738
Compensation expense related to stock options	5,065,654	2,497,254
Common stock issued as payment for services		149,815
Amortization of debt discount		70,408
Amortization of debt issuance costs		17,002
Gain on early extinguishment of debt	(249,458)
Impairment loss on property and equipment	27,204,349
Decrease in fair value of warrant liability	(20,179,761)
Loss on disposal of equipment	13,347
Interest accrued on long-term debt	453,045
Changes in operating assets and liabilities:
Prepaid expenses and other receivables	(471,760)	(894,849)
Accounts payable	(2,417,702)	378,776
Accrued expenses	(1,854,106)	1,134,276
Current portion of restructuring obligation	292,951
Deferred liabilities	(55,000)	(82,500)
Manufacturing research and development obligation	181,684	200,104
Net cash used in operating activities	(24,144,746)	(21,516,409)
Cash flows from investing activities
Purchase of property and equipment	(3,599,040)	(6,039,352)
Proceeds from sale of property and equipment	1,460,615
Proceeds from maturity of short-term investments		1,003,431
Net cash used in investing activities	(2,138,425)	(5,035,921)
Cash flows from financing activities
Proceeds from sale of common stock and warrants	316,152	54,826,380
Proceeds from exercise of common stock warrants		299,932
Proceeds from issuance of convertible note payable	6,000,000
Stock issuance costs		(75,188)
Payments on notes payable	(23,643,786)	(9,538)
Proceeds from exercise of common stock options		132,772
Proceeds from exercise of employee stock purchase plan shares	8,369	136,958
Net cash provided by (used in) financing activities	(17,357,021)	55,211,316
Effect of exchange rate changes on cash	3,900	8,034
Net increase (decrease) in cash and cash equivalents	(43,636,292)	28,667,020
Cash and cash equivalents
Beginning of period	52,973,376	6,163,144
End of period	9,337,084	34,830,164
Supplemental disclosure of cash flow information
Cash paid for interest	568,240	974,526
Supplemental disclosure of noncash investing and financing activities
Issuance of warrants in exchange for early extinguishment of debt	87,100
Stock issuance costs included in accounts payable and accrued expenses		803,352
Interest capitalized on Construction-in-progress		850,551
Purchase of property and equipment included in accounts payable and accrued expenses	2,441,585	782,548
Recognition of asset and facility lease obligation related to construction of new property		10,000
Lease Agreement [Member]
Cash flows from investing activities
Purchase of property and equipment	(1,700,000)
Cash flows from financing activities
Payment on lease obligations		(100,000)
Power Generation Agreements [Member]
Cash flows from financing activities
Payment on lease obligations	$ (37,756)

Note 1 - Organization and Basis

Note 1 - Organization and Basis of Presentation	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]	1. Argos Therapeutics, Inc. (the “Company”), was incorporated in the State of Delaware on May 8, 1997. The Company’s most advanced product candidate is rocapuldencel-T, which it is developing for the treatment of metastatic renal cell carcinoma, (“mRCC”), and other cancers. The Company is currently conducting a pivotal Phase 3 first May 2013 July 2015. February 2017, 290 290 first 2018. 290 290 no 2 2 2 The Company is also developing a separate Arcelis-based product candidate, AGS- 004, 1 2 2b 004 004 2 004 004 Basis of Presentation and Going Concern The accompanying unaudited condensed consolidated financial statements have been prepared by the Company in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) and with the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial information. The year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not not three six June 30, 2017 not may December 31, 2017 10 10 December 31, 2016. The Company’s consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The Company has incurred losses in each year since inception and as of June 30, 2017, $364.6 June 30, 2017, $21.9 $14.5 $9.3 Based upon its current and projected cash flow, the Company notes there is substantial doubt about its ability to continue as a going concern within one three June 30, 2017 not may On March 3, 2017, March 6, 2017, $23.1 five 100,000 $1.30 $23.1 $23.1 As of June 30, 2017, $9.3 $7.4 not March 2017, $1.1 $2.6 June 2017, $6.0 June 2017, $4.9 August 3, 2017, $4.6 June 30, 2017. not September 2017. September 2017 may one one no may Until such time, if ever, as the Company can generate substantial product revenues, it expects to seek to raise additional funds through a combination of equity offerings, debt financings, government contracts, government and other third third no The condensed consolidated financial statements include the accounts of the Company and DC Bio Corp., the Company’s Canadian wholly-owned subsidiary, an unlimited liability corporation incorporated in the Province of Nova Scotia. Significant intercompany transactions and accounts have been eliminated. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant Accounting Policies There have been no three six June 30, 2017, 10 December 31, 2016. Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three December 31, 2016 June 30, 2017, $52.7 $9.1 Recently Issued Accounting Pronouncements Not In May 2014, 2014 09 , Revenue from Contracts with Customers (“ASU 2014 09” 2014 09 not December 15, 2016. August 2015, 2015 14, Revenue from Contracts with Customers: Deferral of the Effective Date, 2014 09 one December 15, 2017, not first 2018. 2016 10, Identifying Performance Obligations and Licensing, two 2014 09 third The Company is currently evaluating the impact that the implementation of this standard will have on the Company’s consolidated financial statements. In August 2016, ASU 2016 15, Statement of Cash Flows (Topic 230 entation of certain items in the statement of cash flows including but not December 15, 2017, January 1, 2018. In February 2016, 2016 02, Leases (Topic 842 2016 02" 2016 02 not 12 12 842 840 Leases December 15, 2018, January 1, 2019. In November 2016, 2016 18, Restricted Cash 2016 18" 2016 18 2016 18 first 2019, 2016 18 not Recently Adopted Accounting Standards In August 2016, 2016 09, Improvements to Employee Share-Based Payment Accounting 2016 09” 2016 09 six June 30, 2017 no

Note 2 - Fair Value of Financia

Note 2 - Fair Value of Financial Instruments	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Fair Value Disclosures [Text Block]	2. The estimated fair values of all of the Company’s financial instruments, excluding long-term debt, approximate their carrying amounts in the consolidated balance sheets as of December 31, 2016 June 30, 2017. As of December 31, 2016 June 30, 2017, December 31, 2016 June 30, 2017, three one three 1, 2, 1, 3, The Company’s Level 1 1 As of June 30, 2017, no 2 The Company’s warrant liability is classified as a Level 3 11 During the six June 30, 2017, no 1, 2, 3 As of December 31, 2016 June 30, 2017, Quoted Prices Significant Significant Balance as of Assets Money-market funds $ 45,389,314 $ — $ — $ 45,389,314 Restricted cash 740,000 — — 740,000 Total assets at fair value $ 46,129,314 $ — $ — $ 46,129,314 Liabilities Warrants $ — $ — $ 20,926,061 $ 20,926,061 Total liabilities at fair value $ — $ — $ 20,926,061 $ 20,926,061 Quoted Prices Significant Significant Balance as of Assets Money-market funds $ 4,079,487 $ — $ — $ 4,079,487 Restricted cash 740,000 — — 740,000 Total assets at fair value $ 4,819,487 $ — $ — $ 4,819,487 Liabilities Warrants $ — $ — $ 746,300 $ 746,300 Total liabilities at fair value $ — $ — $ 746,300 $ 746,300 Changes in the fair value of the Company’s Level 3 six June 30, 2017 Balance as of December 31, 2016 $ 20,926,061 Change in fair value during the period (20,179,761 ) Balance as of June 30, 2017 $ 746,300 The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and estimated fair value of money-market funds included in cash and cash equivalents and restricted cash as of December 31, 2016 June 30, 2017 As of December 31, 2016 Amortized Cost Gross Gross Aggregate Money-market funds $ 45,389,314 $ — $ — $ 45,389,314 Restricted cash 740,000 — — 740,000 $ 46,129,314 $ — $ — $ 46,129,314 As of June 30, 2017 Amortized Cost Gross Gross Aggregate Money-market funds $ 4,079,487 $ — $ — $ 4,079,487 Restricted cash 740,000 — — 740,000 $ 4,819,487 $ — $ — $ 4,819,487 The fair value of the Company’s debt was derived by evaluating the nature and terms of each note, considering the prevailing economic and market conditions as of each balance sheet date and based on the Level 2 December 31, 2016 $29.8 $30.1 June 30, 2017 $6.2 $6.6 6

Note 3 - Restructuring Activiti

Note 3 - Restructuring Activities and Related Impairments of Property and Equipment and Leases	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Restructuring and Related Activities Disclosure [Text Block]	3. As discussed in Note 1, 3 February 2017, 290 4 7, $5.4 $27.2 six June 30, 2017. Workforce Action Plan On March 10, 2017, 46 38% 122 76 44 July 31, 2017. $1.1 six June 30, 2017, $0.3 June 30, 2017. $2.6 six June 30, 2017. CTI Lease Agreement In January 2017, ten two five 40,000 $2.4 first 2018. February 2017 On March 17, 2017 not not 12% March 31, 2017, March 17, 2017. $2.4 $0.7 March 2017 $1.7 April 2017 $0.1 six June 30, 2017, $1.6 $0.9 Impairment of Centerpoint Facility and Construction-in-Progress The Company also determined during the three March 31, 2017 no nine six June 30, 2017, $18.3 June 30, 2017, $7.4 $7.4 June 30, 2017. The Company believes that its current Technology Drive and Patriot Center facilities are sufficient for the manufacture of rocapuldencel-T and AGS- 004 may The restructuring liability during the six June 30, 2017 Severance and Lease and Other Total Balance as of December 31, 2016 $ — $ — $ — Restructuring costs 3,737,176 1,615,590 5,352,766 Acceleration of stock options (2,608,008 ) — (2,608,008 ) Cash payments (836,217 ) (1,615,590 ) (2,451,807 ) Balance as of June 30, 2017 $ 292,951 $ — $ 292,951

Note 4 - Property and Equipment

Note 4 - Property and Equipment	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	4. Property and equipment consist of the following: December 31, June 30, Office furniture and equipment $ 657,875 $ 657,875 Computer equipment 1,018,173 1,029,555 Computer software 3,146,978 3,146,978 Laboratory equipment 5,709,215 6,108,348 Leasehold improvements 2,435,530 2,435,530 Assets related to facility lease obligation 8,070,033 — Construction-in-progress 28,807,957 — Total property and equipment, gross 49,845,761 13,378,286 Less: Accumulated depreciation and amortization (8,894,184 ) (9,323,296 ) Property and equipment, net $ 40,951,577 $ 4,054,990 The Company reviews its property and equipment for impairment whenever events or changes indicate its carrying value may not 3, three March 31, 2017 no $0.7 June 30, 2017 $1.1 six June 30, 2017. $6.1 six June 30, 2017 no Centerpoint Facility and Construction-in-Progress As of December 31, 2016, 8 3, three March 31, 2017 no nine June 30, 2017 $18.3 six June 30, 2017. June 30, 2017, $7.4 $7.4 June 30, 2017. Construction-in-progress under capital leases included $2,372,880 $0 December 31, 2016 June 30, 2017, December 31, 2016 June 30, 2017, $2,652,261 $0, Depreciation and amortization expense was as follows: Three months ended June 30, 2016 $ 237,996 Three months ended June 30, 2017 $ 246,206 Six months ended June 30, 2016 $ 439,738 Six months ended June 30, 2017 $ 490,701

Note 5 - Income Taxes

Note 5 - Income Taxes	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Income Tax Disclosure [Text Block]	5. The Company has incurred net operating losses since inception and is forecasting additional losses through December 31, 2017. no 2017 no June 30, 2017. Due to the Company’s history of losses since inception, there is not December 31, 2016 June 30, 2017, not not

Note 6 - Notes Payable

Note 6 - Notes Payable	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Debt Disclosure [Text Block]	6. Notes payable consist of the following as of December 31, 2016 June 30, 2017: December 31, June 30, Notes payable under the venture loan and security agreement, including accrued interest $ 24,035,029 $ — Less debt discount and debt issuance costs (320,409 ) — Notes payable under the venture loan and security agreement, net 23,714,620 — Convertible note payable to Pharmstandard, including accrued interest — 6,015,616 Promissory note payable to Medinet, including accrued interest 6,403,186 6,574,891 Other notes payable 30,972 22,575 Total notes payable including convertible note payable to Pharmstandard 30,148,778 12,613,082 Less convertible note payable to Pharmstandard, including accrued interest — (6,015,616 ) Less current portion (11,475,480 ) (17,870 ) Long-term portion of notes payable $ 18,673,298 $ 6,579,596 Convertible Note Payable to Pharmstandard. June 15, 2017, $6,000,000 The Company issued the note to Pharmstandard on June 21, 2017, fifth 9.5% may In addition, at Pharmstandard’s election, Pharmstandard may $0.50. not 39.9% 39.9% may not Pharmstandard is the Company’s largest stockholder, and beneficially owned, in the aggregate, shares representing approximately 39.9% July 31, 2017. two Venture Loan Facility. September 2014, $25.0 two $12.5 The Company borrowed the first $12.5 September 2014 second $12.5 August 2015. 9.25% one 0.50% 8.75% one not 10.75%. The Company incurred $449,796 June 30, 2017 The Company made payments with respect to the first $12.5 October 31, 2016, first September 30, 2018. first $625,000 September 30, 2018, $625,000 first second $12.5 18 February 7, 2017, 24 second February 7, 2019. $625,000 February 7, 2019, $625,000 second 3% 24 2% 24 36 1% 36 On March 3, 2017, March 6, 2017, $23.1 five 100,000 $1.30 $23.1 $249,458 six June 30, 2017 Upon the payment of the $23.1 The Company’s obligations under the Loan Agreement were secured by a first not In connection with the Loan Agreement, the Company issued to the Lenders and their affiliates warrants to purchase a total of 82,780 $9.06 second September 29, 2021 September 29, 2014, $338,673 June 30, 2017 Medinet Loan. December 2013, 13, $9.0 3.0% December 31, 2018. first not December 31, 2018, December 31, 2018 may $9.0 December 31, 2013, $6.9 8.0%, $2.1 During the year ended December 31, 2015, $1.0 $0.8 $0.2 December 31, 2016, $2.0 $1.5 $0.5 December 31, 2016 June 30, 2017, $6.4 $6.6 $1.8 $2.0 December 31, 2016 June 30, 2017, $5.3 13 Other Notes. November 2013, $77,832 $30,972 $22,575 December 31, 2016 June 30, 2017, 8.31% 60

Note 7 - Manufacturing Research

Note 7 - Manufacturing Research and Development Obligation	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Research, Development, and Computer Software Disclosure [Text Block]	7. In October 2014, July 2005. Invetech has agreed to defer 30% $5.0 7% 90 four first eight first two December 31, 2016. 10% 100% As of December 31, 2016, $8.2 $5.2 $2.3 $0.6 $3.7 June 30, 2017, $8.3 $5.2 $2.3 $0.7 $5.3 The Invetech Development Agreement requires the parties to discuss in good faith Invetech’s supply of Production Systems for use in manufacturing commercial product. The Company has an obligation to purchase $25.0 third first third may not third The Company is currently in discussions with Invetech regarding the Invetech Development Agreement related to the deferred fees, and the repayment of the fees, including potentially through the conversion of some or all of the outstanding fees into equity of the Company.

Note 8 - Facility Lease Obligat

Note 8 - Facility Lease Obligation, Capital Lease Obligations and Assets Held for Sale	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Leases of Lessee Disclosure [Text Block]	8. Facility Lease Obligation In August 2014, 125,000 $1.7 June 30, 2017. The term of the Lease Agreement is 10 July 1, 2015. six five second $47,972 The Lease Agreement required the Company to provide TKC with a letter of credit. The Company provided the bank that issued the letter of credit on its behalf a security deposit of $1,325,000 $740,000 December 31, 2015 December 31, 2016 June 30, 2017 Under the Lease Agreement, the Company is involved in the construction of the building. To the extent the Company is involved with the structural improvements of the construction project or takes construction risk prior to the commencement of a lease, ASC 840 40 05 5 The initial recording of these assets and liabilities is classified as non-cash investing and financing items, respectively, for purposes of the Company’s consolidated statements of cash flows. Under the Lease Agreement, the Company had an option to purchase the property. In February 2015, $7.4 $1.7 December 31, 2016, October 31, 2016 not no As of December 31, 2016, 3, three March 31, 2017 no nine June 30, 2017 $0.7 six June 30, 2017. $7.9 December 31, 2016 $7.4 June 30, 2017. $7.4 December 31, 2016 June 30, 2017. $18.3 six June 30, 2017 ( 3 Capital Lease Obligations In August 2016, two $32,948 128 $4.2 March 2027. $2.4 December 31, 2016 June 30, 2017, $2.3 $0.1 six June 30, 2017 ( 3

Note 9 - Stockholders' Equity (

Note 9 - Stockholders' Equity (Deficit)	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	9. Common Stock Issued in 2017 In lieu of paying certain annual cash bonuses for 2016, January 2017 25% 2016 January 13, 2017. 80,105 $394,534 100% April 17, 2017, three June 30, 2017, one 7,378 three June 30, 2017, one 46,664 $20,999 At-the-market Offering in 2017 In May 2015, may $30 may 415 1933, not May 14, 2015. 3% six June 30, 2017, 829,096 $0.3 13,945,932 $4.6 July 1, 2017 August 3, 2017. December 31, 2016, 872,682 $5.5

Note 10 - Stock Incentive Plan

Note 10 - Stock Incentive Plan	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	10. In January 2014, 2014 “2014 2014 January 2014, may 1,951,182 357,841 2008 “2008 2008 February 12, 2014 381,250 2008 first January 1, 2015 January 1, 2024, 2,309,023 4% first July 28, 2017 2014 2014 6,000,000 may 2014 first December 31, 2024 2,690,977 2014 11,611,506 first December 31, 2018 December 31, 2024, 5,000,000 four 4% Also in January 2014, 2014 “2014 2014 2014 may 10% 2014 2014 Under the terms of the 2014 85% 85% first first September 2, 2014 February 27, 2015. first 13,054 85% first $9.83 February 27, 2015 $9.02, $54,508. second March 2, 2015 August 31, 2015. second 20,301 85% second $9.02 August 31, 2015 $6.21, $72,800. third September 1, 2015 February 29, 2016. third 36,290 85% third $6.24 $4.44 February 29, 2016, $107,455. fourth March 1, 2016 August 31, 2016. fourth 30,157 85% fourth $4.91 $4.95 August 31, 2016, $63,788. fifth September 1, 2016 February 28, 2017. fifth 8,562 85% fifth $4.95 $1.15 February 28, 2017, $30,064. sixth March 1, 2017 August 31, 2017. 85% sixth $1.20 $0.36 June 30, 2017, $12,492 Upon the exercise of stock options, vesting of other awards and purchase of shares through the 2014 2014 2014 2014 June 30, 2017, 1,365,052 2014 237,989 2014 The Company recorded the following share-based compensation expense: Three Months Ended June 30, Six Months Ended June 30, 2016 2017 2016 2017 Research and development $ 1,019,199 $ 653,624 $ 1,447,800 $ 2,261,911 General and administrative 726,038 764,359 1,250,639 2,803,743 Total stock-based compensation expense $ 1,745,237 $ 1,417,983 $ 2,698,439 $ 5,065,654 Allocations to research and development and general and administrative expenses are based upon the department to which the associated employee reported. No three June 30, 2016, 18 $0.6 3, $0.2 $2.6 three six June 30, 2017, 58 March April 2017. During the three June 30, 2016, 899,456 $5.71 $10.97 565,000 $7.41 $5.95 three June 30, 2017, not During the six June 30, 2016, 1,210,106 $2.16 $10.97 565,000 $7.41 $5.95 six June 30, 2017, 1,382,084 $1.35 $5.05 The following table summarizes the Company’s stock option activity during the six June 30, 2017: Number of Weighted Weighted Outstanding as of December 31, 2016 4,902,828 $ 6.07 Granted 1,382,084 $ 4.87 Exercised - $ - Cancelled (675,062 ) $ 4.85 Outstanding as of June 30, 2017 5,609,850 $ 5.92 6.17 Exercisable as of June 30, 2017 3,299,044 $ 5.93 4.31 Vested and expected to vest as of June 30, 2017 5,431,918 $ 5.92 6.08 Valuation Assumptions for Stock Option Plans and Employee Stock Purchase Plan The employee stock-based compensation expense recognized was determined using the Black-Scholes option valuation model. Option valuation models require the input of subjective assumptions and these assumptions can vary over time. The weighted average assumptions used were as follows for the periods indicated: Stock Option Plan Employee Stock Purchase Plan Six Months Ended June 30, Six Months Ended June 30, 2016 2017 2016 2017 Risk-free interest rate 1.53 % 2.27 % 0.50 % 0.79 % Dividend yield 0 % 0 % 0 % 0 % Expected option term (in years) 7 7 0.5 0.5 Volatility 82 % 86 % 141 % 210 %

Note 11 - Warrants

Note 11 - Warrants	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Warrants [Text Block]	11. In March 2016, $19,882,915 3,652,430 2,739,323 $5.35. March 14, 2021 June 29, 2016, $29,824,520 5,478,672 4,109,005 $5.35. June 29, 2021 June 2016, 56,062 $299,932 In August 2016, $50.0 9,090,909 6,818,181 $5.50 “August 2016 August 2, 2021 As discussed in Note 6 September 2014, second September 29, 2021 March 6, 2017, five 100,000 $1.30 $87,100 June 30, 2017. As of June 30, 2017, 13,793,227 five Type of Warrant and Classification Number of Shares Exercise Price Expiration Common stock - Equity 82,780 $ 9.06 9/29/21 Common stock - Equity 2,683,261 $ 5.35 3/14/21 Common stock - Equity 4,109,005 $ 5.35 6/29/21 Common stock - Liability 6,818,181 $ 5.50 8/02/21 Common stock - Equity 100,000 $ 1.30 3/06/22 The August 2016 June 30 2017, August 2016 August 2016 August 2016 August 2016 Exercise price $ 5.50 Expiration date August 2, 2021 Total shares issuable on exercise 6,818,181 The fair value of the August 2016 five zero August 2016 August 2016 six June 30, 2017 The assumptions used by the Company to determine the fair value of the August 2016 December 31, 2016 June 30, 2017: December 31, 2016 June 30, 2017 Exercise price of warrants $ 5.50 $ 5.50 Closing underlying stock price on date of valuation $ 4.90 $ 0.36 Expected stock price volatility 84 % 108 % Expected life (in years) 4.58 4.08 Risk-free interest rate 1.93 % 1.72 % Expected dividend yield 0.0 % 0.0 % Valuation per common share underlying each warrant $ 3.07 $ 0.11 Total liability for warrants on the balance sheet $ 20,926,061 $ 746,300 Decrease in fair value $ 1,007,352 $ 20,179,761 In November 2013, 13,188,251 499,788 $5.82 August 2, 2017, not

Note 12 - Revenue and Concentra

Note 12 - Revenue and Concentration of Credit Risk	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Concentration Risk Disclosure [Text Block]	12. In September 2006, 004. $39.8 $38.4 $1.4 September 2010, September 2010. May 2013. $5.4 May 2013 September 2015. $0.5 September 18, 2014 2 004 June 29, 2016, July 31, 2018. not The Company recognizes revenue from reimbursements earned in connection with the contract as reimbursable costs are incurred and revenues from the achievement of milestones under the NIH and NIAID contract upon the accomplishment of any such milestone. For the three June 30, 2016 2017, $461,143 $42,193, six June 30, 2016 2017, $552,572 $119,952, $38.0 June 30, 2017 June 30, 2017, $1.8 December 31, 2016 June 30, 2017, $136,140 $42,193, no

Note 13 - Collaboration Agreeme

Note 13 - Collaboration Agreements	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Long-term Contracts or Programs Disclosure [Text Block]	13. Pharmstandard License Agreement In August 2013, first may Under the terms of the license agreement, Pharmstandard licensed the Company rights to clinical data generated by Pharmstandard under the agreement and granted the Company an option to obtain an exclusive license outside of the Pharmstandard Territory to develop and commercialize improvements to the Company’s Arcelis technology generated by Pharmstandard under the agreement, a non-exclusive worldwide royalty-free license to Pharmstandard improvements to manufacture products using the Company’s Arcelis technology and a license to specified follow-on licensed products generated by Pharmstandard outside of the Pharmstandard Territory, each on terms to be negotiated upon the Company’s request for a license. In addition, Pharmstandard agreed to pay the Company pass-through royalties on net sales of all licensed products in the low single digits until it has generated a specified amount of aggregate net sales. Once the net sales threshold is achieved, Pharmstandard will pay the Company royalties on net sales of specified licensed products, including rocapuldencel-T, in the low double digits below 20%. twelfth first no third third The agreement will terminate upon expiration of the royalty term, upon which all licenses will become fully paid-up perpetual exclusive licenses. Either party may may third may In November 2013, 499,788 $5.82 not February 2014. Green Cross License Agreement In July 2013, first may Under the terms of the license, Green Cross has agreed to pay the Company $500,000 $500,000 20% fifteenth first The agreement will terminate upon expiration of the royalty term, which is 15 first may may third Medinet License Agreement In December 2013, October 2014. $9.0 In addition, under this agreement, the Company granted Medinet an option to acquire a nonexclusive, royalty-bearing license under the Company’s Arcelis technology to sell in Japan rocapuldencel-T and other products for the treatment of mRCC. The Company refers to the option as the sale option and the license as the sale license. This option expired on April 30, 2016. may may not In consideration for the manufacturing license, Medinet paid the Company $1.0 $9.0 $9.0 $5.0 first first $1.0 July 2015 second $2.0 June 2016, September 30, 2016 $6.0 In December 2013, $9.0 3.0% December 31, 2018. not December 31, 2018, December 31, 2018 may The Company recorded the initial $1.0 $9.0 December 31, 2013, $6.9 8.0%, $2.1 December 31, 2015, $1.0 $0.8 $0.2 December 31, 2016, $2.0 $1.5 $0.5 December 31, 2016, $6.4 $1.8 June 30, 2017, $6.6 $2.0 December 31, 2016 June 30, 2017, $5.3 The agreement will terminate upon expiration of the royalty term, upon which all licenses will become fully paid up, perpetual non-exclusive licenses. Either party may may third Lummy License Agreement On April 7, 2015, first December 2016. Under the terms of the License Agreement, the parties will share relevant data, and the Company will have a right to reference Lummy HK data for purposes of its development programs under the Arcelis technology. In addition, Lummy HK has granted to the Company an exclusive, royalty-free license under and to any and all Lummy HK improvements to the Arcelis technology conceived or reduced to practice by Lummy HK (“Lummy HK Improvements”) and Lummy HK data to develop and/or commercialize products (“Arcelis-Based Products”) outside the Territory, an exclusive, royalty-free license under and to any and all investigational new drug applications ("INDs") and other regulatory approvals and Lummy HK trademarks used for an Arcelis-Based Product to develop and/or commercialize an Arcelis-Based Product outside the Territory and a non-exclusive, worldwide, royalty-free license under any Lummy HK Improvements and Lummy HK data to manufacture Arcelis-Based Products anywhere in the world. Lummy HK has the right to reference the Company’s data, INDs and other regulatory filings and submissions for the purpose of developing and obtaining regulatory approval of Licensed Products in the Territory. Pursuant to the License Agreement, Lummy HK will pay the Company royalties on net sales and an aggregate of up to $20.5 10 first may may third

Note 14 - Net Loss Per Share

Note 14 - Net Loss Per Share	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Earnings Per Share [Text Block]	14. Basic and diluted net loss per share of common stock was determined by dividing net loss by the weighted average of shares of common stock outstanding during the period. The Company’s potentially dilutive shares, which include options to purchase common stock and warrants, have not The following table presents the computation of basic and diluted net loss per share of common stock: Three Months Ended June 30, Six Months Ended June 30, 2016 2017 2016 2017 Net loss $ (12,606,245 ) $ (8,538,611 ) $ (25,426,433 ) $ (32,618,690 ) Weighted average common shares outstanding, basic and diluted 26,066,160 41,374,852 24,336,393 41,344,356 Net loss per share, basic and diluted $ (0.48 ) $ (0.21 ) $ (1.04 ) $ (0.79 ) The following potentially dilutive securities have been excluded from the computation of diluted weighted average common shares outstanding, as they would be antidilutive: Three Months Ended June 30, Six Months Ended June 30, 2016 2017 2016 2017 Stock options outstanding 3,716,923 5,879,915 3,635,868 5,869,056 Warrants outstanding 2,854,320 13,793,227 1,724,422 13,757,315

Note 15 - Legal Proceedings

Note 15 - Legal Proceedings	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Legal Matters and Contingencies [Text Block]	15. On March 14, 2017, 1934 February 7, 2014 February 21, 2017 ( June 23, 2017. September 18, 2017 60 may Other than as described above, the Company is not not

Significant Accounting Policies

Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2017
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation and Going Concern The accompanying unaudited condensed consolidated financial statements have been prepared by the Company in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) and with the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial information. The year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not not three six June 30, 2017 not may December 31, 2017 10 10 December 31, 2016. The Company’s consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The Company has incurred losses in each year since inception and as of June 30, 2017, $364.6 June 30, 2017, $21.9 $14.5 $9.3 Based upon its current and projected cash flow, the Company notes there is substantial doubt about its ability to continue as a going concern within one three June 30, 2017 not may On March 3, 2017, March 6, 2017, $23.1 five 100,000 $1.30 $23.1 $23.1 As of June 30, 2017, $9.3 $7.4 not March 2017, $1.1 $2.6 June 2017, $6.0 June 2017, $4.9 August 3, 2017, $4.6 June 30, 2017. not September 2017. September 2017 may one one no may Until such time, if ever, as the Company can generate substantial product revenues, it expects to seek to raise additional funds through a combination of equity offerings, debt financings, government contracts, government and other third third no The condensed consolidated financial statements include the accounts of the Company and DC Bio Corp., the Company’s Canadian wholly-owned subsidiary, an unlimited liability corporation incorporated in the Province of Nova Scotia. Significant intercompany transactions and accounts have been eliminated.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three December 31, 2016 June 30, 2017, $52.7 $9.1
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Issued Accounting Pronouncements Not In May 2014, 2014 09 , Revenue from Contracts with Customers (“ASU 2014 09” 2014 09 not December 15, 2016. August 2015, 2015 14, Revenue from Contracts with Customers: Deferral of the Effective Date, 2014 09 one December 15, 2017, not first 2018. 2016 10, Identifying Performance Obligations and Licensing, two 2014 09 third The Company is currently evaluating the impact that the implementation of this standard will have on the Company’s consolidated financial statements. In August 2016, ASU 2016 15, Statement of Cash Flows (Topic 230 entation of certain items in the statement of cash flows including but not December 15, 2017, January 1, 2018. In February 2016, 2016 02, Leases (Topic 842 2016 02" 2016 02 not 12 12 842 840 Leases December 15, 2018, January 1, 2019. In November 2016, 2016 18, Restricted Cash 2016 18" 2016 18 2016 18 first 2019, 2016 18 not Recently Adopted Accounting Standards In August 2016, 2016 09, Improvements to Employee Share-Based Payment Accounting 2016 09” 2016 09 six June 30, 2017 no

Note 2 - Fair Value of Financ23

Note 2 - Fair Value of Financial Instruments (Tables)	6 Months Ended
	Jun. 30, 2017
Notes Tables
Fair Value, Assets Measured on Recurring Basis [Table Text Block]	Quoted Prices Significant Significant Balance as of Assets Money-market funds $ 45,389,314 $ — $ — $ 45,389,314 Restricted cash 740,000 — — 740,000 Total assets at fair value $ 46,129,314 $ — $ — $ 46,129,314 Liabilities Warrants $ — $ — $ 20,926,061 $ 20,926,061 Total liabilities at fair value $ — $ — $ 20,926,061 $ 20,926,061 Quoted Prices Significant Significant Balance as of Assets Money-market funds $ 4,079,487 $ — $ — $ 4,079,487 Restricted cash 740,000 — — 740,000 Total assets at fair value $ 4,819,487 $ — $ — $ 4,819,487 Liabilities Warrants $ — $ — $ 746,300 $ 746,300 Total liabilities at fair value $ — $ — $ 746,300 $ 746,300
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	Balance as of December 31, 2016 $ 20,926,061 Change in fair value during the period (20,179,761 ) Balance as of June 30, 2017 $ 746,300
Financial Instruments [Table Text Block]	As of December 31, 2016 Amortized Cost Gross Gross Aggregate Money-market funds $ 45,389,314 $ — $ — $ 45,389,314 Restricted cash 740,000 — — 740,000 $ 46,129,314 $ — $ — $ 46,129,314 As of June 30, 2017 Amortized Cost Gross Gross Aggregate Money-market funds $ 4,079,487 $ — $ — $ 4,079,487 Restricted cash 740,000 — — 740,000 $ 4,819,487 $ — $ — $ 4,819,487

Note 3 - Restructuring Activi24

Note 3 - Restructuring Activities and Related Impairments of Property and Equipment and Leases (Tables)	6 Months Ended
	Jun. 30, 2017
Notes Tables
Schedule of Restructuring Reserve by Type of Cost [Table Text Block]	Severance and Lease and Other Total Balance as of December 31, 2016 $ — $ — $ — Restructuring costs 3,737,176 1,615,590 5,352,766 Acceleration of stock options (2,608,008 ) — (2,608,008 ) Cash payments (836,217 ) (1,615,590 ) (2,451,807 ) Balance as of June 30, 2017 $ 292,951 $ — $ 292,951

Note 4 - Property and Equipme25

Note 4 - Property and Equipment (Tables)	6 Months Ended
	Jun. 30, 2017
Notes Tables
Property, Plant and Equipment [Table Text Block]	December 31, June 30, Office furniture and equipment $ 657,875 $ 657,875 Computer equipment 1,018,173 1,029,555 Computer software 3,146,978 3,146,978 Laboratory equipment 5,709,215 6,108,348 Leasehold improvements 2,435,530 2,435,530 Assets related to facility lease obligation 8,070,033 — Construction-in-progress 28,807,957 — Total property and equipment, gross 49,845,761 13,378,286 Less: Accumulated depreciation and amortization (8,894,184 ) (9,323,296 ) Property and equipment, net $ 40,951,577 $ 4,054,990
Depreciation and Amortization Expense [Member]
Notes Tables
Property, Plant and Equipment [Table Text Block]	Three months ended June 30, 2016 $ 237,996 Three months ended June 30, 2017 $ 246,206 Six months ended June 30, 2016 $ 439,738 Six months ended June 30, 2017 $ 490,701

Note 6 - Notes Payable (Tables)

Note 6 - Notes Payable (Tables)	6 Months Ended
	Jun. 30, 2017
Notes Tables
Schedule of Debt [Table Text Block]	December 31, June 30, Notes payable under the venture loan and security agreement, including accrued interest $ 24,035,029 $ — Less debt discount and debt issuance costs (320,409 ) — Notes payable under the venture loan and security agreement, net 23,714,620 — Convertible note payable to Pharmstandard, including accrued interest — 6,015,616 Promissory note payable to Medinet, including accrued interest 6,403,186 6,574,891 Other notes payable 30,972 22,575 Total notes payable including convertible note payable to Pharmstandard 30,148,778 12,613,082 Less convertible note payable to Pharmstandard, including accrued interest — (6,015,616 ) Less current portion (11,475,480 ) (17,870 ) Long-term portion of notes payable $ 18,673,298 $ 6,579,596

Note 10 - Stock Incentive Plan

Note 10 - Stock Incentive Plan (Tables)	6 Months Ended
	Jun. 30, 2017
Notes Tables
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	Three Months Ended June 30, Six Months Ended June 30, 2016 2017 2016 2017 Research and development $ 1,019,199 $ 653,624 $ 1,447,800 $ 2,261,911 General and administrative 726,038 764,359 1,250,639 2,803,743 Total stock-based compensation expense $ 1,745,237 $ 1,417,983 $ 2,698,439 $ 5,065,654
Share-based Compensation, Stock Options, Activity [Table Text Block]	Number of Weighted Weighted Outstanding as of December 31, 2016 4,902,828 $ 6.07 Granted 1,382,084 $ 4.87 Exercised - $ - Cancelled (675,062 ) $ 4.85 Outstanding as of June 30, 2017 5,609,850 $ 5.92 6.17 Exercisable as of June 30, 2017 3,299,044 $ 5.93 4.31 Vested and expected to vest as of June 30, 2017 5,431,918 $ 5.92 6.08
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Stock Option Plan Employee Stock Purchase Plan Six Months Ended June 30, Six Months Ended June 30, 2016 2017 2016 2017 Risk-free interest rate 1.53 % 2.27 % 0.50 % 0.79 % Dividend yield 0 % 0 % 0 % 0 % Expected option term (in years) 7 7 0.5 0.5 Volatility 82 % 86 % 141 % 210 %

Note 11 - Warrants (Tables)

Note 11 - Warrants (Tables)	6 Months Ended
	Jun. 30, 2017
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Type of Warrant and Classification Number of Shares Exercise Price Expiration Common stock - Equity 82,780 $ 9.06 9/29/21 Common stock - Equity 2,683,261 $ 5.35 3/14/21 Common stock - Equity 4,109,005 $ 5.35 6/29/21 Common stock - Liability 6,818,181 $ 5.50 8/02/21 Common stock - Equity 100,000 $ 1.30 3/06/22
Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]	December 31, 2016 June 30, 2017 Exercise price of warrants $ 5.50 $ 5.50 Closing underlying stock price on date of valuation $ 4.90 $ 0.36 Expected stock price volatility 84 % 108 % Expected life (in years) 4.58 4.08 Risk-free interest rate 1.93 % 1.72 % Expected dividend yield 0.0 % 0.0 % Valuation per common share underlying each warrant $ 3.07 $ 0.11 Total liability for warrants on the balance sheet $ 20,926,061 $ 746,300 Decrease in fair value $ 1,007,352 $ 20,179,761
August 2016, Warrant [Member]
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	August 2016 Exercise price $ 5.50 Expiration date August 2, 2021 Total shares issuable on exercise 6,818,181

Note 14 - Net Loss Per Share (T

Note 14 - Net Loss Per Share (Tables)	6 Months Ended
	Jun. 30, 2017
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended June 30, Six Months Ended June 30, 2016 2017 2016 2017 Net loss $ (12,606,245 ) $ (8,538,611 ) $ (25,426,433 ) $ (32,618,690 ) Weighted average common shares outstanding, basic and diluted 26,066,160 41,374,852 24,336,393 41,344,356 Net loss per share, basic and diluted $ (0.48 ) $ (0.21 ) $ (1.04 ) $ (0.79 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Three Months Ended June 30, Six Months Ended June 30, 2016 2017 2016 2017 Stock options outstanding 3,716,923 5,879,915 3,635,868 5,869,056 Warrants outstanding 2,854,320 13,793,227 1,724,422 13,757,315

Note 1 - Organization and Bas30

Note 1 - Organization and Basis of Presentation (Details Textual) - USD ($)	Mar. 06, 2017	Aug. 03, 2017	Aug. 03, 2017	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016	Jun. 21, 2017	Dec. 31, 2015
Retained Earnings (Accumulated Deficit)				$ (364,605,507)		$ (364,605,507)		$ (331,986,817)
Assets, Current				21,892,279		21,892,279		55,501,794
Liabilities, Current				$ 14,483,622		$ 14,483,622		30,609,838
Extinguishment of Debt, Amount	$ 23,100,000
Class of Warrant or Right, Term	5 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				13,793,227		13,793,227
Cash and Cash Equivalents, at Carrying Value				$ 9,337,084	$ 34,830,164	$ 9,337,084	$ 34,830,164	52,973,376		$ 6,163,144
Working Capital				7,400,000		7,400,000
Allocated Share-based Compensation Expense				1,417,983	$ 1,745,237	5,065,654	$ 2,698,439
Cash, Uninsured Amount				$ 9.10		9.10		52.70
Sales Agreement, At-the-market Offering [Member]
Proceeds from Issuance of Common Stock						300,000		$ 5,500,000
Sales Agreement, At-the-market Offering [Member] | Subsequent Event [Member]
Proceeds from Issuance of Common Stock		$ 4,600,000	$ 4,900,000
Convertible Note Payable to Pharmstandard [Member]
Debt Instrument, Face Amount									$ 6,000,000
Employee Severance [Member]
Severance Costs						1,100,000
Allocated Share-based Compensation Expense						$ 2,600,000
Common Stock [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	100,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 1.30

Note 2 - Fair Value of Financ31

Note 2 - Fair Value of Financial Instruments (Details Textual) - USD ($) $ in Millions	Jun. 30, 2017	Dec. 31, 2016
Long-term Debt, Fair Value	$ 6.2	$ 29.8
Long-term Debt	$ 6.6	$ 30.1

Note 2 - Fair Value of Financ32

Note 2 - Fair Value of Financial Instruments - Fair Value of Financial Instruments (Details) - Fair Value, Measurements, Recurring [Member] - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Liabilities at fair value	$ 746,300	$ 20,926,061
Assets at fair value	4,819,487	46,129,314
Warrant Liabilities [Member]
Liabilities at fair value	746,300	20,926,061
Fair Value, Inputs, Level 1 [Member]
Liabilities at fair value
Assets at fair value	4,819,487	46,129,314
Fair Value, Inputs, Level 1 [Member] | Warrant Liabilities [Member]
Liabilities at fair value
Fair Value, Inputs, Level 2 [Member]
Liabilities at fair value
Assets at fair value
Fair Value, Inputs, Level 2 [Member] | Warrant Liabilities [Member]
Liabilities at fair value
Fair Value, Inputs, Level 3 [Member]
Liabilities at fair value	746,300	20,926,061
Assets at fair value
Fair Value, Inputs, Level 3 [Member] | Warrant Liabilities [Member]
Liabilities at fair value	746,300	20,926,061
Money Market Funds [Member]
Assets at fair value	4,079,487	45,389,314
Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]
Assets at fair value	4,079,487	45,389,314
Money Market Funds [Member] | Fair Value, Inputs, Level 2 [Member]
Assets at fair value
Money Market Funds [Member] | Fair Value, Inputs, Level 3 [Member]
Assets at fair value
Restricted Cash, Long-Term [Member]
Assets at fair value	740,000	740,000
Restricted Cash, Long-Term [Member] | Fair Value, Inputs, Level 1 [Member]
Assets at fair value	740,000	740,000
Restricted Cash, Long-Term [Member] | Fair Value, Inputs, Level 2 [Member]
Assets at fair value
Restricted Cash, Long-Term [Member] | Fair Value, Inputs, Level 3 [Member]
Assets at fair value

Note 2 - Fair Value of Financ33

Note 2 - Fair Value of Financial Instruments - Changes in Fair Value for Warrants (Details) - Warrant Liability [Member]	6 Months Ended
	Jun. 30, 2017USD ($)
Balance	$ 20,926,061
Change in fair value during the period	(20,179,761)
Balance	$ 746,300

Note 2 - Fair Value of Financ34

Note 2 - Fair Value of Financial Instruments - Financial Instruments (Details) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Aggregate Fair Value	$ 4,819,487	$ 46,129,314
Amortized Cost Basis	4,819,487	46,129,314
Gross Unrealized Holding Gains
Gross Unrealized Holding Losses
Money Market Funds [Member]
Aggregate Fair Value	4,079,487	45,389,314
Amortized Cost Basis	4,079,487	45,389,314
Gross Unrealized Holding Gains
Gross Unrealized Holding Losses
Restricted Cash, Long-Term [Member]
Aggregate Fair Value	740,000	740,000
Amortized Cost Basis	740,000	740,000
Gross Unrealized Holding Gains
Gross Unrealized Holding Losses

Note 3 - Restructuring Activi35

Note 3 - Restructuring Activities and Related Impairments of Property and Equipment and Leases (Details Textual)	Mar. 10, 2017	Apr. 30, 2017USD ($)	Mar. 31, 2017USD ($)	Jan. 31, 2017USD ($)	Apr. 30, 2017	Jun. 30, 2017USD ($)	Jun. 30, 2016USD ($)	Jun. 30, 2017USD ($)	Jun. 30, 2016USD ($)	May 01, 2017	Mar. 17, 2017
Restructuring Charges						$ 344,474		$ 5,352,766
Impairment of Long-Lived Assets to be Disposed of								27,204,349
Acceleration of Stock Options								2,608,008
Construction in Progress [Member]
Impairment of Long-Lived Assets to be Disposed of								6,100,000
Restructuring Charges [Member]
Lease Termination Fee								1,600,000
CTI Facility [Member]
Security Deposit				$ 2,400,000
Lessee, Operating Lease, Interest Rate Per Annum											12.00%
Payments for Unpaid Construction		$ (1,700,000)	$ (700,000)
Lease Arrangement, Refund of Security Deposit		$ 100,000
Lessee, Operating Lease, Term of Contract				10 years
Lessee Leasing Arrangements, Operating Leases, Number of Renewal Terms				2
Lessee, Operating Lease, Renewal Term				5 years
CTI Facility [Member] | Construction in Progress [Member]
Impairment of Long-Lived Assets to be Disposed of								900,000
Centerpoint Facility [Member]
Assets Held-for-sale, Not Part of Disposal Group						7,400,000		7,400,000
Capital Lease Obligations, Noncurrent						7,400,000		7,400,000
Centerpoint Facility [Member] | Construction in Progress [Member]
Impairment of Long-Lived Assets to be Disposed of								18,300,000
Employee Severance [Member]
Restructuring Charges								3,737,176
Restructuring and Related Cost, Number of Positions Eliminated	46				58		18
Restructuring and Related Cost, Number of Positions Eliminated, Period Percent	38.00%
Number of Employees before Restructuring	122
Number of Employees after Restructuring	76									44
Severance Costs								1,100,000
Restructuring and Related Cost, Incurred but Not yet Paid						300,000		300,000
Acceleration of Stock Options						$ 200,000	$ 600,000	$ 2,608,008

Note 3 - Restructuring Activi36

Note 3 - Restructuring Activities and Related Impairments of Property and Equipment and Leases - Restructuring Liability (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Balance as of December 31, 2016
Restructuring costs	$ 344,474		5,352,766
Acceleration of stock options			(2,608,008)
Cash payments			(2,451,807)
Balance as of June 30, 2017	292,951		292,951
Employee Severance [Member]
Balance as of December 31, 2016
Restructuring costs			3,737,176
Acceleration of stock options	(200,000)	$ (600,000)	(2,608,008)
Cash payments			(836,217)
Balance as of June 30, 2017	292,951		292,951
Facility Closing [Member]
Balance as of December 31, 2016
Restructuring costs			1,615,590
Acceleration of stock options
Cash payments			(1,615,590)
Balance as of June 30, 2017

Note 4 - Property and Equipme37

Note 4 - Property and Equipment (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Assets Held-for-sale, Not Part of Disposal Group, Current	$ 10,341,529		$ 10,341,529		$ 1,452,172
Impairment of Long-Lived Assets to be Disposed of			27,204,349
Property, Plant and Equipment, Gross	13,378,286		13,378,286		49,845,761
Centerpoint Facility [Member]
Assets Held-for-sale, Not Part of Disposal Group	7,400,000		7,400,000
Capital Lease Obligations, Noncurrent	7,400,000		7,400,000
Power Generation Agreements [Member]
Capital Lease Obligations, Noncurrent	2,166,046		2,166,046		2,202,966
Various Equipment [Member]
Assets Held-for-sale, Not Part of Disposal Group, Current	700,000		700,000
Impairment of Long-Lived Assets to be Disposed of			1,100,000
Construction in Progress [Member]
Impairment of Long-Lived Assets to be Disposed of			6,100,000
Property, Plant and Equipment, Gross					28,807,957
Accumulated Capitalized Interest Costs	0		0		2,652,261
Construction in Progress [Member] | Centerpoint Facility [Member]
Impairment of Long-Lived Assets to be Disposed of			18,300,000
Construction in Progress [Member] | Power Generation Agreements [Member]
Impairment of Long-Lived Assets to be Disposed of			100,000
Assets Held-for-sale, Not Part of Disposal Group	2,300,000		2,300,000
Property, Plant and Equipment, Gross	$ 0		$ 0		$ 2,372,880

Note 4 - Property and Equipme38

Note 4 - Property and Equipment - Property and Equipment (Details) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Property and equipment, gross	$ 13,378,286	$ 49,845,761
Less: Accumulated depreciation and amortization	(9,323,296)	(8,894,184)
Property and equipment, net	4,054,990	40,951,577
Office Furniture and Equipment [Member]
Property and equipment, gross	657,875	657,875
Computer Equipment [Member]
Property and equipment, gross	1,029,555	1,018,173
Computer Software [Member]
Property and equipment, gross	3,146,978	3,146,978
Laboratory Equipment [Member]
Property and equipment, gross	6,108,348	5,709,215
Leasehold Improvements [Member]
Property and equipment, gross	2,435,530	2,435,530
Assets Held under Capital Leases [Member]
Property and equipment, gross		8,070,033
Construction in Progress [Member]
Property and equipment, gross		$ 28,807,957

Note 4 - Property and Equipme39

Note 4 - Property and Equipment - Depreciation and Amortization Expense (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Depreciation and amortization expense	$ 246,206	$ 237,996	$ 490,701	$ 439,738

Note 5 - Income Taxes (Details

Note 5 - Income Taxes (Details Textual) $ in Thousands	6 Months Ended
	Jun. 30, 2017USD ($)
Income Tax Expense (Benefit)	$ 0

Note 6 - Notes Payable (Details

Note 6 - Notes Payable (Details Textual)	Mar. 06, 2017USD ($)$ / sharesshares	Sep. 29, 2014USD ($)	Aug. 31, 2015USD ($)	Dec. 31, 2013USD ($)	Nov. 30, 2013USD ($)	Jun. 30, 2017USD ($)$ / sharesshares	Jun. 30, 2016USD ($)	Jun. 30, 2017USD ($)$ / sharesshares	Jun. 30, 2016USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2013USD ($)	Feb. 07, 2019USD ($)	Sep. 30, 2018USD ($)	Jun. 21, 2017USD ($)$ / shares
Deferred Credits and Other Liabilities, Noncurrent						$ 6,668,500		$ 6,668,500		$ 6,723,500
Extinguishment of Debt, Amount	$ 23,100,000
Class of Warrant or Right, Term	5 years
Gain (Loss) on Extinguishment of Debt								$ 249,458
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares						13,793,227		13,793,227
Medinet [Member]
Debt Instrument, Increase, Accrued Interest								$ 2,000,000		1,800,000
Debt Instrument, Interest Rate, Effective Percentage				8.00%								8.00%
Reduction in Notes Payable										1,500,000	$ 800,000
Reduction in Deferred Liability										500,000	200,000
Proceeds from Notes Payable				$ 9,000,000
Notes Payable				$ 6,900,000		$ 6,600,000		$ 6,600,000		6,400,000		$ 6,900,000
Debt Instrument, Interest Rate, Stated Percentage				3.00%								3.00%
Common Stock [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares	100,000
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 1.30
Pharmstandard [Member]
Percentage of Outstanding Common Stock Owned by Related Party								39.90%
Convertible Note Payable to Pharmstandard [Member]
Debt Instrument, Interest Rate, Stated Percentage															9.50%
Debt Instrument, Convertible, Conversion Price | $ / shares															$ 0.50
Debt Instrument, Convertible, Conversion Prerequisite, Ownership Percentage Can Not Exceed If Converted															39.90%
Debt Instrument, Face Amount															$ 6,000,000
Venture Loan and Security Agreement [Member]
Debt Related Commitment Fees and Debt Issuance Costs		$ 449,796
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares						82,780		82,780
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares						$ 9.06		$ 9.06
Debt Instrument, Unamortized Discount		$ 338,673
Debt Instrument, One-Month LIBOR Basis Rate		0.50%
Debt Instrument, Face Amount		$ 25,000,000
Venture Loan and Security Agreement [Member] | Prepayment on or Before Twenty Four Months of Funding Date [Member]
Debt Instrument, Prepayment Penalty, Percentage of Balance						3.00%		3.00%
Venture Loan and Security Agreement [Member] | Prepayment After Twenty Four Months But on or Before Thirty Six Months [Member]
Debt Instrument, Prepayment Penalty, Percentage of Balance						2.00%		2.00%
Venture Loan and Security Agreement [Member] | Prepayment After Thirty Six Months of Funding Date [Member]
Debt Instrument, Prepayment Penalty, Percentage of Balance						1.00%		1.00%
Venture Loan and Security Agreement [Member] | Maximum [Member]
Debt Instrument, Interest Rate, Stated Percentage		10.75%
Venture Loan and Security Agreement [Member] | LIBOR Rate In Excess of a Half a Percent [Member]
Debt Instrument, Basis Spread on Variable Rate		9.25%
Venture Loan and Security Agreement [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument, Basis Spread on Variable Rate		8.75%
Venture Loan and Security Agreement [Member] | Primary Tranche [Member]
Debt Instrument Tranche Amount		$ 12,500,000
Proceeds from Loans		$ 12,500,000	$ 12,500,000
Venture Loan and Security Agreement [Member] | Primary Tranche [Member] | Primary Payment Period [Member]
Debt Instrument, Term								1 year 180 days
Venture Loan and Security Agreement [Member] | Primary Tranche [Member] | Secondary Payment Period [Member]
Debt Instrument, Term								2 years
Venture Loan and Security Agreement [Member] | Primary Tranche [Member] | Scenario, Forecast [Member]
Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid														$ 625,000
Venture Loan and Security Agreement [Member] | Secondary Tranche [Member] | Scenario, Forecast [Member]
Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid													$ 625,000
December 2013 Note [Member]
Debt Instrument, Increase, Accrued Interest								$ 2,000,000		1,800,000
Debt Instrument, Interest Rate, Effective Percentage				8.00%								8.00%
Deferred Credits and Other Liabilities, Noncurrent				$ 2,100,000		$ 5,300,000		5,300,000		5,300,000		$ 2,100,000
Proceeds from Notes Payable												9,000,000
Notes Payable				$ 6,900,000		$ 6,600,000		$ 6,600,000		6,400,000		$ 6,900,000
Debt Instrument, Interest Rate, Stated Percentage				3.00%								3.00%
Debt Instrument, Face Amount				$ 9,000,000								$ 9,000,000
December 2013 Note [Member] | Manufacturing License [Member]
Deferred Credits and Other Liabilities, Noncurrent										2,000,000	$ 1,000,000
November 2013 Note [Member]
Debt Instrument, Number of Payments						60		60
Proceeds from Notes Payable					$ 77,832
Notes Payable						$ 22,575		$ 22,575		$ 30,972
Debt Instrument, Interest Rate, Stated Percentage						8.31%		8.31%

Note 6 - Notes Payable - Notes

Note 6 - Notes Payable - Notes Payable (Details) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Long-term debt	$ 6,600,000	$ 30,100,000
Less long-term debt	(6,600,000)	(30,100,000)
Less current portion	(17,870)	(11,475,480)
Long-term portion of notes payable	6,579,596	18,673,298
Venture Loan and Security Agreement [Member]
Long-term debt, gross		24,035,029
Less debt discount and debt issuance costs		(320,409)
Long-term debt		23,714,620
Less long-term debt		(23,714,620)
Convertible Note Payable to Pharmstandard [Member]
Long-term debt	6,015,616
Less long-term debt	(6,015,616)
December 2013 Note [Member]
Long-term debt	6,574,891	6,403,186
Less long-term debt	(6,574,891)	(6,403,186)
July 2012 Note [Member]
Long-term debt	22,575	30,972
Less long-term debt	(22,575)	(30,972)
Notes Payable Including Convertible Note Payable to Pharmstandard [Member]
Long-term debt	12,613,082	30,148,778
Less long-term debt	$ (12,613,082)	$ (30,148,778)

Note 7 - Manufacturing Resear43

Note 7 - Manufacturing Research and Development Obligation (Details Textual) - USD ($)	Oct. 29, 2014	Jun. 30, 2017	Dec. 31, 2016
Research and Development Obligation, Current		$ 5,273,458	$ 3,653,203
Invetech Pty Ltd [Member]
Bonus Payment Upon Successful Completion of Clinical Trials Percentage of Payment	10.00%
Research and Development Obligation Deferred Fees		5,200,000	5,200,000
Research and Development Obligation Estimated Bonus Payment		2,300,000	2,300,000
Research and Development Obligation Accrued Interest		700,000	600,000
Research and Development Obligation, Current		5,300,000	3,700,000
Research and Development Obligation		8,300,000	$ 8,200,000
Contractual Obligation		$ 25,000,000
Invetech Pty Ltd [Member]
Deferred Research and Development Manufacturing Service Costs Percentage	30.00%
Maximum Deferred Research and Development Manufacturing Service Costs	$ 5,000,000
Interest Rate on Deferred Research and Development Manufacturing Costs	7.00%
Period from Trigger Event for Repayment of Deferred Costs	90 days
Number of Installments for Repayment in One Year	4
Number of Installments for Repayment in Two Years	8

Note 8 - Facility Lease Oblig44

Note 8 - Facility Lease Obligation, Capital Lease Obligations and Assets Held for Sale (Details Textual)	Aug. 18, 2014USD ($)ft²	Aug. 31, 2016USD ($)	Jun. 30, 2017USD ($)	Jun. 30, 2016USD ($)	Jun. 30, 2017USD ($)	Jun. 30, 2016USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)	Feb. 28, 2015USD ($)
Assets Held-for-sale, Not Part of Disposal Group, Current			$ 10,341,529		$ 10,341,529		$ 1,452,172
Payments to Acquire Property, Plant, and Equipment					3,599,040	$ 6,039,352
Property, Plant and Equipment, Gross			13,378,286		13,378,286		49,845,761
Impairment of Long-Lived Assets to be Disposed of					27,204,349
Various Equipment [Member]
Assets Held-for-sale, Not Part of Disposal Group, Current			700,000		700,000
Impairment of Long-Lived Assets to be Disposed of					1,100,000
Construction in Progress [Member]
Property, Plant and Equipment, Gross							28,807,957
Impairment of Long-Lived Assets to be Disposed of					6,100,000
Lease Agreement [Member]
Lessee Leasing Arrangements, Renewal Term	5 years
Lessee Leasing Arrangements, Number of Renewal Terms	6
Capital Lease, Future Monthly Payments	$ 47,972
Security Deposit	$ 1,325,000
Capital Leases, Balance Sheet, Assets by Major Class, Net							7,900,000		$ 7,400,000
Facility Lease Obligation Building Area | ft²	125,000
Payments to Acquire Property, Plant, and Equipment					1,700,000		1,700,000
Lessee Leasing Arrangements, Term of Contract	10 years
Assets Held-for-sale, Not Part of Disposal Group			7,400,000		7,400,000		7,400,000
Lease Agreement [Member] | Restricted Cash [Member]
Security Deposit								$ 740,000
Centerpoint Facility [Member]
Assets Held-for-sale, Not Part of Disposal Group			7,400,000		7,400,000
Centerpoint Facility [Member] | Construction in Progress [Member]
Impairment of Long-Lived Assets to be Disposed of					18,300,000
Power Generation Agreements [Member]
Lessee Leasing Arrangements, Term of Contract		10 years 240 days
Capital Leases, Future Minimum Payments Due		$ 4,200,000
Capital Leases, Number of Contracts		2
Capital Leases, Monthly Payments		$ 32,948
Power Generation Agreements [Member] | Construction in Progress [Member]
Property, Plant and Equipment, Gross			0		0		$ 2,372,880
Assets Held-for-sale, Not Part of Disposal Group			$ 2,300,000		2,300,000
Impairment of Long-Lived Assets to be Disposed of					$ 100,000

Note 9 - Stockholders' Equity45

Note 9 - Stockholders' Equity (Deficit) (Details Textual) - USD ($)	May 08, 2015	Aug. 03, 2017	Jan. 31, 2017	Aug. 03, 2017	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016	Apr. 17, 2017
Restricted Stock Awards Granted in Lieu of Annual Cash Bonuses, Shares, Percentage of Annual Cash Bonus Used in Calculation			25.00%
Stock Issued During Period, Shares, Restricted Stock Award, Gross			80,105
Stock Issued During Period, Value, Restricted Stock Award, Gross			$ 394,534
Restricted Stock Awards, Lapsing Right of Repurchase, Percentage of Underlying Shares										100.00%
Allocated Share-based Compensation Expense					$ 1,417,983	$ 1,745,237	$ 5,065,654	$ 2,698,439
Sales Agreement, At-the-market Offering [Member]
Stock Issued During Period, Shares, New Issues							829,096		872,682
Proceeds from Issuance of Common Stock							$ 300,000		$ 5,500,000
Sales Agreement, At-the-market Offering [Member] | Subsequent Event [Member]
Stock Issued During Period, Shares, New Issues		13,945,932
Proceeds from Issuance of Common Stock		$ 4,600,000		$ 4,900,000
Cowen and Company LLC [Member] | Maximum [Member]
Common Stock Sales Agreement, Amount	$ 30,000,000
Common Stock Sales Agreement, Commission of Gross Proceeds	3.00%
General and Administrative Expense [Member]
Allocated Share-based Compensation Expense					$ 764,359	$ 726,038	$ 2,803,743	$ 1,250,639
Employee [Member]
Stock Issued During Period, Shares, Share-based Compensation, Gross					46,664
Employee [Member] | General and Administrative Expense [Member]
Allocated Share-based Compensation Expense					$ 20,999
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period					7,378

Note 10 - Stock Incentive Pla46

Note 10 - Stock Incentive Plan (Details Textual)	Jul. 28, 2017shares	Mar. 10, 2017	Feb. 29, 2016USD ($)$ / sharesshares	Aug. 31, 2015USD ($)$ / sharesshares	Apr. 30, 2017	Jun. 30, 2017USD ($)$ / sharesshares	Jun. 30, 2016USD ($)$ / sharesshares	Jun. 30, 2017USD ($)$ / sharesshares	Jun. 30, 2017USD ($)$ / sharesshares	Feb. 28, 2017USD ($)$ / sharesshares	Aug. 31, 2016USD ($)$ / sharesshares	Jun. 30, 2016USD ($)$ / sharesshares	Feb. 27, 2015USD ($)$ / sharesshares	Mar. 01, 2017$ / shares	Sep. 01, 2016$ / shares	Mar. 01, 2016$ / shares	Sep. 01, 2015$ / shares	Mar. 02, 2015$ / shares	Sep. 02, 2014$ / shares	Feb. 12, 2014shares	Jan. 31, 2014shares
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit | $ / shares							$ 5.71		$ 1.35			$ 2.16
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit | $ / shares							$ 10.97		$ 5.05			$ 10.97
Acceleration of Stock Options | $									$ 2,608,008
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross						0	899,456		1,382,084			1,210,106
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares									$ 4.87
Allocated Share-based Compensation Expense | $						$ 1,417,983	$ 1,745,237		$ 5,065,654			$ 2,698,439
Executive Committee Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross							565,000					565,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares							$ 7.41					$ 7.41
Share Price | $ / shares							$ 5.95					$ 5.95
Employee Severance [Member]
Acceleration of Stock Options | $						$ 200,000	$ 600,000		2,608,008
Restructuring and Related Cost, Number of Positions Eliminated		46			58		18
Allocated Share-based Compensation Expense | $									$ 2,600,000
The 2014 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized						2,309,023		2,309,023	2,309,023
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized, Percent of Shares Outstanding						4.00%		4.00%	4.00%
Common Stock, Capital Shares Reserved for Future Issuance						1,365,052		1,365,052	1,365,052
The 2014 Plan [Member] | Subsequent Event [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized	6,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Maximum Automatic Annual Increase	2,690,977
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized, Before Annual Increases	11,611,506
Share-based Compensation Arrangement by Share-based Payment Award, Maximum Future Increases in the Number of Shares Authorized	5,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Future Increases in the Number of Shares Authorized, Percent of Shares Outstanding	4.00%
The 2014 Plan [Member] | Initial Authorization [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized																					1,951,182
The 2014 Plan [Member] | Additional Authorization [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized																					357,841
The 2008 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant																				381,250
The 2014 ESPP [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate						10.00%		10.00%	10.00%
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent									85.00%
Common Stock, Capital Shares Reserved for Future Issuance						237,989		237,989	237,989
Share Price | $ / shares			$ 4.44	$ 6.21		$ 0.36		$ 0.36	$ 0.36	$ 1.15	$ 4.95		$ 9.02	$ 1.20	$ 4.95	$ 4.91	$ 6.24	$ 9.02	$ 9.83
Allocated Share-based Compensation Expense | $			$ 107,455	$ 72,800				$ 12,492		$ 30,064	$ 63,788		$ 54,508
Employee Stock Purchase Plan (ESPP), Number of Shares Allocated			36,290	20,301						8,562	30,157		13,054

Note 10 - Stock Incentive Pla47

Note 10 - Stock Incentive Plan - Stock-based Compensation Expense (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Stock-based compensation expense	$ 1,417,983	$ 1,745,237	$ 5,065,654	$ 2,698,439
Research and Development Expense [Member]
Stock-based compensation expense	653,624	1,019,199	2,261,911	1,447,800
General and Administrative Expense [Member]
Stock-based compensation expense	$ 764,359	$ 726,038	$ 2,803,743	$ 1,250,639

Note 10 - Stock Incentive Pla48

Note 10 - Stock Incentive Plan - Stock Option Activity (Details) - $ / shares	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Number of Shares Outstanding, Beginning Balance (in shares)			4,902,828
Weighted Average Exercise Price, Outstanding, Beginning Balance (in dollars per share)			$ 6.07
Weighted Average Exercise Price, Outstanding, Ending Balance (in dollars per share)	$ 5.92		$ 5.92
Weighted Average Contractual Term, Outstanding, Ending Balance (Year)			6 years 62 days
Number of Shares Exercisable (in shares)	3,299,044		3,299,044
Weighted Average Exercise Price, Exercisable (in dollars per share)	$ 5.93		$ 5.93
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	0	899,456	1,382,084	1,210,106
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price			$ 4.87
Number of Shares Exercised (in shares)
Weighted Average Exercise Price, Exercised (in dollars per share)
Number of Shares Cancelled (in shares)			(675,062)
Weighted Average Exercise Price, Cancelled (in dollars per share)			$ 4.85
Number of Shares Outstanding, Ending Balance (in shares)	5,609,850		5,609,850
Weighted Average Contractual Term, Exercisable (Year)			4 years 113 days
Number of Shares Vested and Expected to Vest (in shares)	5,431,918		5,431,918
Weighted Average Exercise Price, Vested and Expected to Vest (in dollars per share)	$ 5.92		$ 5.92
Weighted Average Contractual Term, Vested and Expected to Vest (Year)			6 years 29 days

Note 10 - Stock Incentive Pla49

Note 10 - Stock Incentive Plan - Stock Option Valuation Assumptions (Details)	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Stock Option Plans [Member]
Risk-free interest rate	2.27%	1.53%
Dividend yield	0.00%	0.00%
Expected option term (in years) (Year)	7 years	7 years
Volatility	86.00%	82.00%
Employee Stock Purchase Plan [Member]
Risk-free interest rate	0.79%	0.50%
Dividend yield	0.00%	0.00%
Expected option term (in years) (Year)	182 days	182 days
Volatility	210.00%	141.00%

Note 11 - Warrants (Details Tex

Note 11 - Warrants (Details Textual) - USD ($)	Mar. 06, 2017	Jun. 29, 2016	Mar. 14, 2016	Aug. 31, 2016	Jun. 30, 2016	Nov. 30, 2013	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016	Aug. 02, 2016
Class of Warrant or Right, Term	5 years
Proceeds from Warrant Exercises								$ 299,932
Class of Warrant or Right, Number of Securities Called by Warrants or Rights							13,793,227
August 2016, Warrant [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights										$ 5.50
Warrants and Rights Outstanding							$ 746,300		$ 20,926,061
Class of Warrant or Right, Number of Securities Called by Warrants or Rights										6,818,181
Fair Value Assumptions, Expected Dividend Rate				0.00%			0.00%		0.00%
Lenders and Affiliates [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 1.30
Class of Warrant or Right, Term	5 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	100,000
Lenders and Affiliates [Member] | Additional Paid-in Capital [Member]
Warrants and Rights Outstanding							$ 87,100
Pharmstandard [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights						$ 5.82
Class of Warrant or Right, Number of Securities Called by Warrants or Rights						499,788
Conversion of Stock, Shares Issued						13,188,251
Private Placement [Member] | Investors [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 5.35	$ 5.35
Class of Warrant or Right, Exercised During Period					56,062
Proceeds from Warrant Exercises					$ 299,932
Stock Issued During Period, Value, New Issues		$ 29,824,520	$ 19,882,915
Stock Issued During Period, Shares, New Issues		5,478,672	3,652,430
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		4,109,005	2,739,323
Underwritten Offering [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 5.50
Total Purchase Price of Shares and Warrants Sold				$ 50,000,000
Stock Issued During Period, Shares, New Issues				9,090,909
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				6,818,181

Note 11 - Warrants - Outstandin

Note 11 - Warrants - Outstanding Warrants (Details)	6 Months Ended
	Jun. 30, 2017$ / sharesshares
Common stock - Equity (in shares)	13,793,227
Warrant One [Member]
Common stock - Equity (in dollars per share) | $ / shares	$ 9.06
Common stock - Equity	Sep. 29, 2021
Common stock - Equity (in shares)	82,780
Warrant Two [Member]
Common stock - Equity (in dollars per share) | $ / shares	$ 5.35
Common stock - Equity	Mar. 14, 2021
Common stock - Equity (in shares)	2,683,261
Warrant Three [Member]
Common stock - Equity (in dollars per share) | $ / shares	$ 5.35
Common stock - Equity	Jun. 29, 2021
Common stock - Equity (in shares)	4,109,005
Warrant Four [Member]
Common stock - Equity (in dollars per share) | $ / shares	$ 5.50
Common stock - Equity	Aug. 2, 2021
Common stock - Equity (in shares)	6,818,181
Warrant Five [Member]
Common stock - Equity (in dollars per share) | $ / shares	$ 1.30
Common stock - Equity	Mar. 6, 2022
Common stock - Equity (in shares)	100,000

Note 11 - Warrants - August 201

Note 11 - Warrants - August 2016, Warrants (Details) - $ / shares	Aug. 02, 2016	Jun. 30, 2017
Common stock - Equity (in shares)		13,793,227
August 2016, Warrant [Member]
Common stock - Equity (in dollars per share)	$ 5.50
Common stock - Equity	Aug. 2, 2021
Common stock - Equity (in shares)	6,818,181

Note 11 - Warrants - Warrants V

Note 11 - Warrants - Warrants Valuation Assumptions (Details) - USD ($)	1 Months Ended	3 Months Ended		6 Months Ended		12 Months Ended
	Aug. 31, 2016	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Decrease in fair value of warrant liability		$ 177,563		$ (20,179,761)
August 2016, Warrant [Member]
Exercise price of warrants (in dollars per share)		$ 5.50		$ 5.50		$ 5.50
Closing underlying stock price on date of valuation (in dollars per share)		$ 0.36		$ 0.36		$ 4.90
Expected stock price volatility				108.00%		84.00%
Expected life (in years) (Year)				4 years 29 days		4 years 211 days
Risk-free interest rate				1.72%		1.93%
Expected dividend yield	0.00%			0.00%		0.00%
Valuation per common share underlying each warrant (in dollars per share)				$ 0.11		$ 3.07
Warrants and Rights Outstanding		$ 746,300		$ 746,300		$ 20,926,061
Decrease in fair value of warrant liability				$ 20,179,761		$ 1,007,352

Note 12 - Revenue and Concent54

Note 12 - Revenue and Concentration of Credit Risk (Details Textual) - USD ($)	Sep. 18, 2014	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Sep. 30, 2015	Jun. 30, 2017	Dec. 31, 2016	Sep. 30, 2006
Revenues		$ 69,693	$ 488,643	$ 174,952	$ 635,072
NIH & NIAID [Member]
Unattained Funds, Contracted Commitment									$ 39,800,000
Increase in Unattained Funds, Contracted Commitment						$ 5,400,000
Revenues		42,193	$ 461,143	119,952	$ 552,572		$ 38,000,000
Remaining Unattained Funds Contracted Commitment		1,800,000		1,800,000			1,800,000
Accounts Receivable, Net, Current		$ 42,193		$ 42,193			$ 42,193	$ 136,140
NIH & NIAID [Member] | Operating Expense [Member]
Unattained Funds, Contracted Commitment									38,400,000
NIH & NIAID [Member] | Other Specified [Member]
Unattained Funds, Contracted Commitment									$ 1,400,000
NIH [Member]
Increase in Unattained Funds, Contracted Commitment	$ 500,000

Note 13 - Collaboration Agree55

Note 13 - Collaboration Agreements (Details Textual) - USD ($)	Jul. 31, 2013	Jun. 30, 2016	Jul. 31, 2015	Dec. 31, 2013	Jun. 30, 2017	Dec. 31, 2016	Dec. 31, 2015	Nov. 30, 2013	Aug. 31, 2013
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					13,793,227
Revenue Recognition Milestone Method, Maximum Revenue					$ 20,500,000
License Agreement Royalty Term					10 years
Deferred Credits and Other Liabilities, Noncurrent					$ 6,668,500	$ 6,723,500
Medinet [Member]
Debt Instrument, Face Amount				$ 9,000,000
Pharmstandard [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights								499,788
Class of Warrant or Right, Exercise Price of Warrants or Rights								$ 5.82
Pharmstandard [Member] | Scenario, Plan [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights								499,788
Green Cross [Member]
Royalty Contract Term	15 years
Green Cross [Member] | Initial Submission of Application for Regulatory Approval [Member]
Royalty Guarantees, Commitments, Amount	$ 500,000
Green Cross [Member] | Initial Regulatory Approval [Member]
Royalty Guarantees, Commitments, Amount	$ 500,000
Medinet [Member]
Debt Instrument, Principal Balance		$ 6,000,000
Proceeds from License Fees Received		$ 2,000,000	$ 1,000,000	1,000,000
Proceeds from Notes Payable				9,000,000
Royalty Guarantees, Commitments, Amount				5,000,000
Deferred Revenue, Additions						2,000,000
Notes Payable				$ 6,900,000	6,600,000	6,400,000
Debt Instrument, Increase, Accrued Interest					2,000,000	1,800,000
Debt Instrument, Interest Rate, Stated Percentage				3.00%
Debt Instrument, Interest Rate, Effective Percentage				8.00%
Deferred Revenue							$ 1,000,000
Reduction in Notes Payable						1,500,000	800,000
Reduction in Deferred Liability						500,000	$ 200,000
Medinet [Member] | Nonsoftware License Arrangement [Member]
Deferred Credits and Other Liabilities, Noncurrent				$ 1,000,000
Medinet [Member] | Below Market Rate Adjustment [Member]
Deferred Credits and Other Liabilities, Noncurrent				2,100,000	$ 5,300,000	$ 5,300,000
Maximum [Member] | Pharmstandard [Member]
Royalties Percent of Net Sales									20.00%
Maximum [Member] | Green Cross [Member]
Royalties Percent of Net Sales	20.00%
Maximum [Member] | Medinet [Member] | Developmental and Regulatory Milestones [Member]
Royalty Guarantees, Commitments, Amount				$ 9,000,000

Note 14 - Net Loss Per Share -

Note 14 - Net Loss Per Share - Basic and Diluted Net Loss Per Share (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Net loss	$ (8,538,611)	$ (12,606,245)	$ (32,618,690)	$ (25,426,433)
Weighted average common shares outstanding, basic and diluted (in shares)	41,374,852	26,066,160	41,344,356	24,336,393
Net loss per share, basic and diluted (in dollars per share)	$ (0.21)	$ (0.48)	$ (0.79)	$ (1.04)

Note 14 - Net Loss Per Share 57

Note 14 - Net Loss Per Share - Antidilutive Securities (Details) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Employee Stock Option [Member]
Antidilutive Securities (in shares)	5,879,915	3,716,923	5,869,056	3,635,868
Warrant [Member]
Antidilutive Securities (in shares)	13,793,227	2,854,320	13,757,315	1,724,422